

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 September 2011 (22.09.2011)

PCT

(10) International Publication Number
WO 2011/113363 A1

(51) International Patent Classification:

C07C 233/18 (2006.01) *A61P 25/00* (2006.01)
C07C 231/12 (2006.01) *A61P 25/22* (2006.01)
A61K 31/165 (2006.01) *A61P 25/24* (2006.01)
A61P 5/00 (2006.01)

(21) International Application Number:

PCT/CN2011/071912

(22) International Filing Date:

17 March 2011 (17.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201010126263.9 17 March 2010 (17.03.2010) CN

(71) Applicant (for all designated States except US): **LES LABORATOIRES SERVIER** [FR/FR]; 35, Rue de Verdun, 92284 Suresnes Cedex (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHAN, Hanbin** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **YUAN, Zhedong** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **ZHU, Xueyan** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **ZHANG, Peng** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **PAN, Hongjuan** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road,

Jing'an District, Shanghai 200040 (CN). **YU, Xiong** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN).

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building, 26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF



(57) Abstract: An agomelatine hydrobromide hydrate of formula (I), in which X is Br, preparation method and use thereof as well as pharmaceutical composition containing it are provided. The solubility of the agomelatine hydrobromide hydrate obtained by the present method is significantly higher than that of agomelatine. Therefore, it is more suitable for manufacturing pharmaceutical formulations. In addition, the product has higher stability and purity. The present product of high purity can be obtained through a simple process, rather than process with complicated steps.

WO 2011/113363 A1